Clinical Trials Logo

Clinical Trial Summary

Clinical experience investigation (CEI) is to be conducted to confirm the following to characterise safety and efficacy of Tagrisso Tablets in actual clinical use.

1. Incidence of adverse drug reactions (ADRs) in actual clinical use

2. Factors which may affect safety and efficacy of the product (especially analysis of the incidence and risk factors of interstitial lung disease (ILD) events)

3. Information of ADRs not expected from "Precautions for Use" of the package insert in Japan


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms

  • All Patients Treated With the Product

NCT number NCT02756039
Study type Observational
Source AstraZeneca
Contact
Status Completed
Phase
Start date May 25, 2016
Completion date August 31, 2018